Hepatocellular Carcinoma (HCC) Treatment Market Size, Share and Global Trend by Treatment (Interventional Radiology, Chemotherapy, Radiation Therapy, Surgery, Targeted Therapy, Immunotherapy), By End User (Hospitals, Clinics, Cancer Rehabilitation Centers, Ambulatory Surgery Centers), and Regional Forecast, 2024-2032

Hepatocellular Carcinoma (HCC) is known as malignant hepatoma and is the major malignancy of the liver occurring in patients with chronic liver diseases and cirrhosis. The hepatic tumors proliferate with local expansion, spreading in the intrahepatic region and finally distant metastases. In 2015, in U.S., approximately 39,230 people were affected with intrahepatic bile duct cancer.

The major risks associated with Hepatocellular Carcinoma are Hepatitis B virus (HBV) infection and hepatitis C virus (HCV) infection, alcoholic cirrhosis, metabolic syndrome, biliary cirrhosis, and chronic liver injury. In April 2018, Eli Lilly and Company completed Phase 3 research study of Cyramza (ramucirumab) as a single agent in the second-line treatment of people with hepatocellular carcinoma. 

To gain extensive insights into the market, Request for Customization

Technology advancements in the detection and treatment of the hepatocellular carcinoma, personalized medicine, and cost-effective treatment procedures are some of the factors driving the growth of global hepatocellular carcinoma treatment market. Additionally, high exposure to toxins and increasing incidence of hepatocellular carcinoma are some of the factors driving the growth of Global Hepatocellular Carcinoma Treatment Market.

The factor that is expected to inhibit the growth of the market is stringent regulatory processes, the low success rate in clinical trials for drugs, and lack of awareness among the underdeveloped countries.  

Key Players Covered 

Some of the major companies that are present in the global Hepatocellular Carcinoma (HCC) Treatment market are Novartis AG, Bayer AG, Merck & Co., Inc., Bristol-Myers Squibb Company, AbbVie Inc., Johnson & Johnson Services, Inc., CELGENE CORPORATION, Amgen Inc., Teva Pharmaceutical Industries Ltd., Pfizer Inc., Takeda Pharmaceutical Company Limited, and others. 

SEGMENTATION 

The interventional radiology segment can be further divided into chemoembolization, intra-arterial chemotherapy, radiofrequency ablation, and others. NanoKnife is a minimally invasive option for some liver cancer patients with an inoperable tumor that is typically less than three centimeters. This segment is expected to have higher demand during the forecast period. 

Key Insights 

• Prevalence of Hepatocellular Carcinoma, Key Countries/ Region
• Pipeline Analysis, Key Players  

Regional Analysis 

North America is expected to hold a dominant position in the global hepatocellular carcinoma treatment market over the forecast period, owing to the increasing prevalence of the chronic liver diseases and rising number of clinical trials for the treatment of cancer undertaken by the manufacturers to address the unmet medical needs of the patients. According to a survey conducted by the Health Science Department, University of California, Los Angeles, (UCLA), 2017, hepatocellular carcinoma (HCC) represents more than 70.0% of all liver cancers diagnosed in the U.S., with an estimated 40,000 people diagnosed with liver cancer in 2017 and more than 28,000 deaths reported due to hepatocellular carcinoma. Europe and Asia Pacific are expected to register significant CAGR in the forecast period, owing to a rising number of research and development activities undertaken by the manufacturers in the region to develop effective therapies and treatment methods to treat hepatocellular carcinoma. According to the World Health Organization, in Europe and Japan, an estimated 63,000 and 36,000 people were diagnosed with liver cancer in 2017, respectively. 

Key Industry Developments

• In August 2018, Eisai Co., Ltd., received FDA approval for lenvatinib capsules for first-line treatment of patients with unresectable hepatocellular carcinoma (HCC).
• In September 2018, Exelixis, Inc., received approval for Cabometyx for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib.
• AstraZeneca currently developing Durvalumab is under phase 3 clinical trial and expected to launch the by 2021.
• Lion TCR Pte. Ltd., is developing HBV antigen specific TCR redirected T cell under phase 2 trial for the Hepatocellular Carcinoma (HCC) is expected to get over by 2020.